Literature DB >> 19893682

Meningitis caused by Rhodotorula mucilaginosa in human immunodeficiency virus seropositive patient.

V P Baradkar1, S Kumar.   

Abstract

Rhodotorula species may be responsible for systemic infection in immunocompromised patients. Meningitis by Rhodotorula species in human immunodeficiency virus (HIV) infected persons has been reported previously. We report a case of meningitis caused by Rhodotorula mucilaginosa in a 36-year-old HIV seropositive male patient who presented with fever, altered sensorium and features of meningeal irritation i.e. neck rigidity. The Cerebrospinal fluid (CSF) cell counts were high, showing 150 cells/mm(3), with 60% lymphocytes and 40% polymorphs, and protein content of 100 mg%; glucose was 60 mg%. The diagnosis was confirmed by culture on Sabouraud's Dextrose agar. The patient was treated successfully with intensive Amphotericin B (1 mg/kg), for two weeks, followed by oral Itraconazole (400 mg daily), for a period of two months. The patient was started on anti retroviral therapy. He did not show any relapse of the symptoms when the last follow up was done six months after the date of discharge.

Entities:  

Keywords:  Human immunodeficiency virus; Rhodotorula; meningitis

Year:  2008        PMID: 19893682      PMCID: PMC2771990          DOI: 10.4103/0972-2327.44561

Source DB:  PubMed          Journal:  Ann Indian Acad Neurol        ISSN: 0972-2327            Impact factor:   1.383


Introduction

Invasive fungal disease continues to be a significant problem among immunocompromised patients. Most fungal infections are caused by commonly recognized opportunistic fungi such as Aspergillus species, Candida species, Cryptococcus neoformans and dimorphic fungi.[1] Fungi like Trichosporon beigelii, Malassezia furfur, Geotrichum candidum and Rhodotorula species are emerging pathogens of immunocompromised patients.[1-3] Rhodotorula species has been reported to cause septicemia, sepsis, meningitis, endocarditis, keratitis, ventriculitis, peritonitis, central venous catheter infection and endophthalmitis.[3-10] We report a case of meningitis caused by Rhodotorula mucilaginosa in an HIV infected patient.

Case History

A 36-year-old male patient presented with a history of headache and fever for the past seven days, and altered sensorium since the last three days. On enquiry, it was found that he had had pulmonary tuberculosis two years back, for which he had received anti tubercular therapy comprising of 2H3 R3 Z3 E3 (H: Isoniazid (600 mg), R: Rifampicin (450 mg), Z: Pyrazinamide (1500 mg), Ethambutol (1200 mg) for two months, followed by 4H 3 R3 (H: Isoniazid (600 mg), R: Rifampicin (450 mg), for a period of four months. On general examination the patient was found to be febrile (100° F); there was no pallor, icterus or lymphadenopathy noted. On neurological examination, the patient was found to have altered sensorium and neck rigidity. Other motor and sensory examinations were unremarkable. The cardiovascular and respiratory system examinations were within normal limits. Abdominal examination per se did not reveal any guarding, rigidity, free fluid or organomegaly. The patient's laboratory investigations revealed hemoglobin (Hb) of 12 gm%, erythrocyte sedimentation rate (ESR) of 8 mm/hr, total leukocyte count (TLC) - 7600/mm 3, with lymphocytes 60% and polymorphs 40%. The liver and kidney functions were within normal limits. An X-ray of the chest did not reveal any abnormality. Serological testing for HIV antibodies was performed using Enzyme linked immunosorbent assay (ELISA), which revealed that he was reactive to HIV 1 antibodies. The CD4 counts were 196 cells/mm3; however, viral load and computerized tomography (CT) scan of the brain was not performed. In view of the altered sensorium and neck rigidity, a lumbar puncture was performed. The cerebrospinal fluid (CSF) was examined by microscopy, with 10% Nigrosin staining, Gram staining, and Ziehl-Neelsen staining, and bacteriological and fungal culture was done. The CSF cell counts were high, showing 150 cells/mm3, with 60% lymphocytes & 40% polymorphs, protein content of 100 mg%; glucose was 60 mg%. Nigrosin staining showed encapsulated budding yeast cells [Fig. 1]. Gram stained smear showed Gram positive budding yeast cells. Initially, presumptive diagnosis of cryptococcal meningitis was made on the basis of Nigrosin mount and Gram staining. Ziehl-Neelsen staining was negative for acid fast bacilli. No organisms grew on bacteriological culture of CSF. A red pasty mucoid growth [Fig. 2] was seen on CSF culture on Sabouraud's Dextrose agar with antibiotics (Chloramphenicol 0.05 mg/L, cycloheximide 0.5 mg/L) and without antibiotics at 25°C and 37°C. Gram staining from colony revealed Gram positive budding yeast cells. These findings, along with the biochemical tests[11] and the absence of ballistospore formation, helped us to diagnose the pathogen as Rhodotorula mucilaginosa and the meningitis as a case of Rhodotorula meningitis. The possibility of contamination was ruled out by repeated isolation from another CSF sample of the patient, collected aseptically, two days after the initial report of capsulated yeasts seen in the CSF was given. The blood cultures of the patient, however, showed no growth in culture.
Figure 1

10% Nigrosin mount (X400) showing capsulated yeasts

Figure 2

Red mucoid colonies of Rhodotorula species on Sabouraud's dextrose agar

10% Nigrosin mount (X400) showing capsulated yeasts Red mucoid colonies of Rhodotorula species on Sabouraud's dextrose agar The patient was administered intravenous Amphotericin B (1 mg/kg/day) for two weeks. He responded well to the treatment, with the fever subsiding after one week of Amphotericin B therapy; he gradually regained consciousness. The patient was later started on oral Itraconazole (400 mg daily) for a period of two months. The patient was discharged after a period of four weeks from the date of admission and was started on anti retroviral therapy namely Zidovudine (300 mg) + Lamivudine (150 mg) + Nevirapine (200 mg), because of his low CD4 counts. The patient had not shown any relapse of symptoms when the last follow up was done six months after the date of discharge.

Discussion

The incidence of fungal infections of Central nervous system (CNS) has shown a steep rise, largely due to the advent of acquired immune deficiency syndrome (AIDS), and the widespread use of broad spectrum antibiotics, steroids and immunosuppressive drugs.[4] Rhodotorula species is emerging in immune compromised patients, especially in HIV infected patients.[1-3] Rhodotorula species is common saprophytes in the environment. However, their etiological role in immunocompromised patients has been described only rarely.[1-3] Rhodotorula fungal infections of the CNS continue to be uncommon. Rhodotorula belongs to the family Sporidiobolaceae and Phylum Basidiomycota.[11] It produces mucoid yeast like soft, pasty colonies with red pigment on Sabouraud's Dextrose agar (SDA) medium. Microscopically, the unicellular cells of this fungus are spherical in shape, size varying from 4 mm to 6 mm, surrounded by a capsule. No ascospores are present. Many species of Rhodotorula have been described, but Rhodotorula mucilaginosa is the commonest species isolated from clinical specimens.[1-3] Rhodotorula species and Cryptococcus neoformans have many similarities and both produce meningitis. Hence each may be mistaken for the other. Rhodotorula species differs from Cryptococcus neoformans in its carotenoid pigments.[1-4] Its isolation from normally sterile sites such as blood and CSF is of greater significance.[5 Rhodotorula species has been reported to cause septicemia, sepsis, meningitis, endocarditis, keratitis, ventriculitis, peritonitis, central venous catheter infection and endophthalmitis.[346101213] Pore and Chen[14] reported a case of Rhodotorula mucilaginosa meningitis in patients with acute lymphoblastic leukemia. He detected encapsulated budding yeast cells and confirmed it by culture. A case of meningitis in HIV infected persons was reported by Gyaurgieva et al[6] Recently Thakur et al.[4] described Rhodotorula mucaliginosa meningitis in an HIV infected patient from Himachal Pradesh, India. The patient was initially on intravenous Amphotericin B; later, intravenous Flucytosine (25 mg/kg) was added. However, in spite of the treatment, the patient died. On the other hand, our patient responded to intravenous Amphotericin B treatment. A study of the susceptibility profile of 29 clinical isolates of Rhodotorula spp. revealed that Fluconazole, itraconazole and voriconazole were inactive in vitro against a majority of Rhodotorula isolates, while Amphotericin B and flucytosine exhibit good activity, being reasonable alternatives for empirical treatment.[15] The new and investigational triazoles all have some in vitro activity, with ravuconazole being the most active.[10] Treatment of Rhodotorula infection involved the removal of central venous catheters if any, and, generally, amphotericin B or fluconazole therapy for 14 days.[11] The recognition of unusual yeasts as agents of occasional life-threatening infections and their unpredictable antifungal susceptibilities increases the burden on the clinical microbiology laboratory to complete species identification and determine minimal inhibitory concentration (MIC). To conclude, Rhodotorula species should be kept in mind while diagnosing and treating cases of meningitis, especially in HIV infected patients.
  13 in total

1.  Endocarditis caused by Rhodotorula successfully treated with 5-fluorocytosine.

Authors:  Y Naveh; A Friedman; D Merzbach; N Hashman
Journal:  Br Heart J       Date:  1975-01

2.  Rhodotorula glutinis keratitis.

Authors:  R Guerra; G M Cavallini; L Longanesi; C Casolari; G Bertoli; F Rivasi; U Fabio
Journal:  Int Ophthalmol       Date:  1992-05       Impact factor: 2.031

3.  Chronic postoperative Rhodotorula endophthalmitis.

Authors:  J K Gregory; J A Haller
Journal:  Arch Ophthalmol       Date:  1992-12

4.  Activities of available and investigational antifungal agents against rhodotorula species.

Authors:  D J Diekema; B Petroelje; S A Messer; R J Hollis; M A Pfaller
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

5.  Meningitis caused by Rhodotorula rubra in an HIV-infected patient.

Authors:  O H Gyaurgieva; T S Bogomolova; G I Gorshkova
Journal:  J Med Vet Mycol       Date:  1996 Sep-Oct

Review 6.  New and emerging yeast pathogens.

Authors:  K C Hazen
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

7.  Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review.

Authors:  Alicia Gomez-Lopez; Emilia Mellado; Juan L Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  J Antimicrob Chemother       Date:  2005-02-04       Impact factor: 5.790

Review 8.  Central venous catheter-associated fungemia due to Rhodotorula spp. --a systematic review.

Authors:  Felipe F Tuon; Gisele M Duboc de Almeida; Silvia F Costa
Journal:  Med Mycol       Date:  2007-08       Impact factor: 4.076

9.  Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates.

Authors:  Aimee K Zaas; Molly Boyce; Wiley Schell; Barbara Alexander Lodge; Jackie L Miller; John R Perfect
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

10.  Meningitis caused by Rhodotorula.

Authors:  R S Pore; J Chen
Journal:  Sabouraudia       Date:  1976-11
View more
  7 in total

1.  Marchiafava-Bignami disease: a rare entity with a poor outcome.

Authors:  Paulo Eduardo Mestrinelli Carrilho; Marcius Benigno Marques Dos Santos; Larisa Piasecki; Amaury Cezar Jorge
Journal:  Rev Bras Ter Intensiva       Date:  2013-03

Review 2.  Meningitis Caused by Rhodotorula mucilaginosa in HIV-Infected Patient: A Case Report and Review of the Literature.

Authors:  Fadzilah Mohd Nor; Lian Huat Tan; Shi Ling Na; Kee Peng Ng
Journal:  Mycopathologia       Date:  2015-03-05       Impact factor: 2.574

3.  Rhodotorula mucilaginosa associacted meningitis: A subacute entity with high mortality. Case report and review.

Authors:  Sotirios Tsiodras; Sotirios Papageorgiou; Joseph Meletiadis; Polydoros Tofas; Vasiliki Pappa; John Panayiotides; Petros Karakitsos; Apostolos Armaganidis; George Petrikkos
Journal:  Med Mycol Case Rep       Date:  2014-09-10

4.  Cell Envelope Integrity and Capsule Characterization of Rhodotorula mucilaginosa Strains from Clinical and Environmental Sources.

Authors:  Johnathan Yockey; Luke Andres; Moleigh Carson; Jeramia J Ory; Amy J Reese
Journal:  mSphere       Date:  2019-06-05       Impact factor: 4.389

5.  Epidemiology of Rhodotorula: an emerging pathogen.

Authors:  Fernanda Wirth; Luciano Z Goldani
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-02

6.  Antarctic Strain of Rhodotorula mucilaginosa UFMGCB 18,377 Attenuates Mucositis Induced by 5-Fluorouracil in Mice.

Authors:  Joana O P A Coutinho; Mônica F Quintanilha; Marina R A Campos; Enio Ferreira; Graciéle C A de Menezes; Luiz H Rosa; Carlos A Rosa; Katia D Vital; Simone O A Fernandes; Valbert N Cardoso; Jacques R Nicoli; Fabiana C P Tiago; Flaviano S Martins
Journal:  Probiotics Antimicrob Proteins       Date:  2021-07-13       Impact factor: 5.265

7.  Rhodotorula mucilaginosa, a quorum quenching yeast exhibiting lactonase activity isolated from a tropical shoreline.

Authors:  Norshazliza Ab Ghani; Joanita Sulaiman; Zahidah Ismail; Xin-Yue Chan; Wai-Fong Yin; Kok-Gan Chan
Journal:  Sensors (Basel)       Date:  2014-04-09       Impact factor: 3.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.